Richard S Levy sold $2.9M of MDGL
director at MADRIGAL PHARMACEUTICALS, INC.. 5,682 shares at an average of $515.44, traded May 22, 2026, filed May 22, 2026.
Score components
- +15RoleDirector
- +25Trade size$2.9M at market
- +5Share of holdings soldSold 21% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001628280-26-037830, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 22, 2026 | SOpen-market sale Common Stock10b5-1 | -40 | $506.68 | $20k | 27,657 | May 22, 2026 |
| May 22, 2026 | SOpen-market sale Common Stock10b5-1 | -320 | $508.24 | $163k | 27,337 | May 22, 2026 |
| May 22, 2026 | SOpen-market sale Common Stock10b5-1 | -151 | $510.36 | $77k | 27,186 | May 22, 2026 |
| May 22, 2026 | SOpen-market sale Common Stock10b5-1 | -610 | $511.40 | $312k | 26,576 | May 22, 2026 |
| May 22, 2026 | SOpen-market sale Common Stock10b5-1 | -439 | $512.50 | $225k | 26,137 | May 22, 2026 |
| May 22, 2026 | SOpen-market sale Common Stock10b5-1 | -40 | $512.97 | $21k | 26,097 | May 22, 2026 |
| May 22, 2026 | SOpen-market sale Common Stock10b5-1 | -343 | $514.67 | $177k | 25,754 | May 22, 2026 |
| May 22, 2026 | SOpen-market sale Common Stock10b5-1 | -657 | $515.92 | $339k | 25,097 | May 22, 2026 |
| May 22, 2026 | SOpen-market sale Common Stock10b5-1 | -723 | $516.87 | $374k | 24,374 | May 22, 2026 |
| May 22, 2026 | SOpen-market sale Common Stock10b5-1 | -1,497 | $517.59 | $775k | 22,877 | May 22, 2026 |
| May 22, 2026 | SOpen-market sale Common Stock10b5-1 | -782 | $518.76 | $406k | 22,095 | May 22, 2026 |
| May 22, 2026 | SOpen-market sale Common Stock10b5-1 | -80 | $519.98 | $42k | 22,015 | May 22, 2026 |
Related signals
Other insiders at MADRIGAL PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $6.2M 11,583 shares | -6% | |
| 30Weak | MDGLsell MADRIGAL PHARMACEUTICALS, INC. | Shannon T Kelley General Counsel | $342k 664 shares | -5% | |
| 35Weak | MDGLsell MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $1.4M 2,500 shares | -1% | |
| 21Weak | MADRIGAL PHARMACEUTICALS, INC. | David Soergel Chief Medical Officer | $517k 1,042 shares | -9% | |
| 40Moderate | MADRIGAL PHARMACEUTICALS, INC. | David Soergel Chief Medical Officer | $435k 844 shares | -7% | |
| 45Moderate | MADRIGAL PHARMACEUTICALS, INC. | Mardi Dier EVP and CFO | $854k 1,982 shares | -14% | |
| 42Moderate | MADRIGAL PHARMACEUTICALS, INC. | Carole Huntsman Chief Commercial Officer | $181k 419 shares | -3% | |
| 41Moderate | MADRIGAL PHARMACEUTICALS, INC. | Shannon T Kelley General Counsel | $155k 360 shares | -3% | |
| 42Moderate | MADRIGAL PHARMACEUTICALS, INC. | Rebecca Taub Pres., R&D, and CMO | $212k 491 shares | -0% | |
| 61Notable | MADRIGAL PHARMACEUTICALS, INC. | William John Sibold President and CEO | $718k 1,663 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.